ANI Pharmaceuticals ANIP Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $285.62M+97.1% | $144.89M-34.5% | $221.12M+315% | $53.23M-49.4% | ||
| $281.08M+26.8% | $221.73M+36.8% | $162.08M-2.0% | $165.44M+28.7% | ||
| $143.07M+4.6% | $136.78M+23.0% | $111.2M+5.5% | $105.36M+29.0% | ||
| $753.12M+42.5% | $528.46M+1.7% | $519.82M+51.0% | $344.26M+7.0% | ||
| $62.48M+9.9% | $56.86M+27.5% | $44.59M+3.1% | $43.25M-17.9% | ||
| $62.48M+4.2% | $59.99M+113% | $28.22M0.0% | $28.22M+1.2% | ||
| $479.53M-11.5% | $541.83M+159% | $209.01M-16.9% | $251.64M-14.4% | ||
| $1.44B+12.1% | $1.28B+42.0% | $904.42M+19.0% | $760.09M-1.5% | ||
| $62.58M+37.1% | $45.66M+24.5% | $36.68M+25.2% | $29.31M+27.6% | ||
| $17.27M+88.3% | $9.17M+979% | $850K0.0% | $850K0.0% | ||
| $278.11M+43.0% | $194.45M+33.7% | $145.48M+46.3% | $99.44M+13.6% | ||
| $291.84M-5.6% | $309.11M+8.5% | $284.82M-0.3% | $285.67M-0.3% | ||
| $899.65M+5.1% | $855.94M+91.6% | $446.82M+6.0% | $421.55M+2.1% | ||
| $3K+50.0% | $2K0.0% | $2K+100% | $1K0.0% | ||
| -$23.1M+77.0% | -$100.28M-25.1% | -$80.13M+17.6% | -$97.29M-104% | ||
| $540.72M+33.9% | $403.68M-6.7% | $432.75M+38.0% | $313.69M-6.0% | ||
| $1.44B+12.1% | $1.28B+42.0% | $904.42M+19.0% | $760.09M-1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can ANI Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.12 — current assets exceed current liabilities.
- Where does ANI Pharmaceuticals's balance sheet data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.